guest ::
| Home > Publications database > Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies. > print |
| Home > Publications database > Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies. > print |
| 001 | 169665 | ||
| 005 | 20240326150822.0 | ||
| 024 | 7 | _ | |a 10.1002/ijc.33725 |2 doi |
| 024 | 7 | _ | |a pmid:34196970 |2 pmid |
| 024 | 7 | _ | |a 0020-7136 |2 ISSN |
| 024 | 7 | _ | |a 1097-0215 |2 ISSN |
| 024 | 7 | _ | |a altmetric:108531281 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-01487 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Papadimitriou, Nikos |b 0 |
| 245 | _ | _ | |a Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies. |
| 260 | _ | _ | |a Bognor Regis |c 2021 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1711462070_22852 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Nov 1;149(9):1659-1669 |
| 520 | _ | _ | |a Dysregulation of tryptophan metabolism has been linked to colorectal tumorigenesis, however, epidemiological studies investigating tryptophan metabolites in relation to colorectal cancer risk are limited. We studied associations of plasma tryptophan, serotonin, and kynurenine with colon cancer risk in two studies with cancer patients and controls, and in one prospective cohort: ColoCare Study (110 patients/153 controls), the Colorectal Cancer Study of Austria (CORSA; 46 patients/390 controls), and the European Prospective Investigation into Cancer and Nutrition (EPIC; 456 matched case-control pairs). Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for colon cancer risk. Tryptophan was inversely associated with colon cancer risk in ColoCare [OR per 1-standard deviation (SD) = 0.44; 95% CI, 0.31-0.64] and EPIC (OR per 1-SD = 0.86; 95% CI, 0.74-0.99). Comparing detectable versus non-detectable levels, serotonin was positively associated with colon cancer in CORSA (OR = 6.39; 95% CI, 3.61-11.3) and EPIC (OR = 2.03; 95% CI, 1.20-3.40). Kynurenine was inversely associated with colon cancer in ColoCare (OR per 1-SD = 0.74; 95% CI, 0.55-0.98), positively associated in CORSA (OR per 1-SD = 1.79; 95% CI, 1.27-2.52), while no association was observed in EPIC. The kynurenine-to-tryptophan ratio was positively associated with colon cancer in ColoCare (OR per 1-SD = 1.38; 95% CI, 1.03-1.84) and CORSA (OR per 1-SD = 1.44; 95% CI, 1.06-1.96), but not in EPIC. These results suggest that higher plasma tryptophan may be associated with lower colon cancer risk, while increased serotonin may be associated with a higher risk of colon cancer. The kynurenine-to-tryptophan ratio may also reflect altered tryptophan catabolism during colon cancer development. This article is protected by copyright. All rights reserved. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a Tryptophan |2 Other |
| 650 | _ | 7 | |a colon cancer |2 Other |
| 650 | _ | 7 | |a kynurenine |2 Other |
| 650 | _ | 7 | |a plasma |2 Other |
| 650 | _ | 7 | |a serotonin |2 Other |
| 700 | 1 | _ | |a Gunter, Marc J |b 1 |
| 700 | 1 | _ | |a Murphy, Neil |0 0000-0003-3347-8249 |b 2 |
| 700 | 1 | _ | |a Gicquiau, Audrey |b 3 |
| 700 | 1 | _ | |a Achaintre, David |b 4 |
| 700 | 1 | _ | |a Brezina, Stefanie |b 5 |
| 700 | 1 | _ | |a Gumpenberger, Tanja |b 6 |
| 700 | 1 | _ | |a Baierl, Andreas |b 7 |
| 700 | 1 | _ | |a Ose, Jennifer |b 8 |
| 700 | 1 | _ | |a Geijsen, Anne Jmr |b 9 |
| 700 | 1 | _ | |a van Roekel, Eline H |b 10 |
| 700 | 1 | _ | |a Gsur, Andrea |0 0000-0002-9795-1528 |b 11 |
| 700 | 1 | _ | |a Gigic, Biljana |b 12 |
| 700 | 1 | _ | |a Habermann, Nina |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Ulrich, Cornelia M |b 14 |
| 700 | 1 | _ | |a Kampman, Ellen |b 15 |
| 700 | 1 | _ | |a Weijenberg, Matty P |b 16 |
| 700 | 1 | _ | |a Ueland, Per-Magne |b 17 |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 18 |u dkfz |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 19 |u dkfz |
| 700 | 1 | _ | |a Krogh, Vittorio |0 0000-0003-0122-8624 |b 20 |
| 700 | 1 | _ | |a Bueno-de-Mesquita, Bas |b 21 |
| 700 | 1 | _ | |a Ardanaz, Eva |b 22 |
| 700 | 1 | _ | |a Travis, Ruth C |b 23 |
| 700 | 1 | _ | |a Schulze, Matthias B |b 24 |
| 700 | 1 | _ | |a Sánchez, Maria-José |b 25 |
| 700 | 1 | _ | |a Colorado-Yohar, Sandra M |b 26 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |0 0000-0003-2237-0128 |b 27 |
| 700 | 1 | _ | |a Scalbert, Augustin |b 28 |
| 700 | 1 | _ | |a Keski-Rahkonen, Pekka |0 0000-0001-9437-3040 |b 29 |
| 773 | _ | _ | |a 10.1002/ijc.33725 |g p. ijc.33725 |0 PERI:(DE-600)1474822-8 |n 9 |p 1659-1669 |t International journal of cancer |v 149 |y 2021 |x 1097-0215 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:169665 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-02-04 |w ger |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-02-04 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-04 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J CANCER : 2019 |d 2021-02-04 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J CANCER : 2019 |d 2021-02-04 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|